Department of Orthopaedics
Sheldon S. Lin, M.D.
Clinical InfoMedical Expertise
Foot and Ankle Injuries and Disorders
University Hospital, Newark
Overlook Hospital, Summit
Insurance Participation: with Provider Number ( where applicable ) The information below is subject to change and should not be relied upon until after it is verified with the insurance company. In addition, psychiatric providers should be contacted directly for information on their participation with managed care and insurance companies.
- CarePoint Health Plans
- Devon Health Services/ULLICO
- FedMed, Inc
- Healthfirst NJ
- Horizon BCBS Managed Care
- Horizon NJ Health
- Prime Health Services, Inc.
- Three Rivers Provider Network
- United Healthcare Community Plan (formerly AmeriChoice of NJ, Inc.)
Dr. Lin completed his undergraduate studies at Pennsylvania State University and received his medical doctorate from Jefferson Medical College of Philadelphia. He completed his residency training in Orthopaedic Surgery at Thomas Jefferson University Hospital with further training in a Foot and Ankle Fellowship under nationally renowned mentors John Gould, M.D., Jeffery E. Johnson, M.D., and Michael S. Shereff, M.D., at the Medical College of Wisconsin.
After completing six years of training, he joined the Faculty in the Department of Orthopaedic Surgery at University Hospital (UMDNJ) in 1996.
Dr. Lin has lectured on various topics on trauma (Traumatic Foot Injury in Trauma Center), Tendon Abnormality (Non-operative Treatment of PTT Dysfunction), and disorders of the foot and ankle in DM (The Diabetic Foot).
Dr. Lin has lectured and published many scientific articles on the latest medical technique (Subtalar Arthrodesis, Non-operative Treatment of PTT, Tendo-Achilles lengthening for equinuus contracture in DM patients with ulcers). He is on staff at UMDNJ-Newark, Overlook Hospital and Morristown Memorial Hospital.
M.D., 1989, Jefferson Medical College of Thomas Jefferson University
Licensure & Certification
American Board of Orthopaedic Surgery - Orthopaedic Surgery
|Ravi Verma, John Koerner, Eric Breitbart, David Paglia, Swaroopa Vaidya, Michael Pinzur and Sheldon Lin Correlation of growth factor levels at the fusion site of diabetic patients undergoing hindfoot arthrodesis and clinical outcome Current Orthopaedic Practice Volume 22 _ Number 3 _ May/June 2011|
|Christopher W. DiGiovanni, MD; Judith Baumhauer, MD; Sheldon S. Lin, MD; Wayne S. Berberian, MD; Adolph S. Flemister, MD; Matthew J. Enna, MD; Peter Evangelista, MD; June Newman, RNP Prospective, Randomized, Multi-Center Feasibility Trial of rhPDGF-BB Versus Autologous Bone Graft in a Foot and Ankle Fusion Model Foot Ankle Int April 32:344 2011|
|Dana T. Graves , Jazia Alblowi , David N. Paglia , James Patrick O’Connor , Sheldon Lin Impact of Diabetes on Fracture Healing J Exp Clin Med 2011;3(1):3|
|Brietbart EA, Meade S, Azad V, Yeh S, Al-Zuge L, Lee YS, Benevenia J, Arinzeh TL, Lin SS. Mesenchymal stem cells accelerate bone allograft incorporation in the presence of diabetes mellitus. J. Orthop. Res. 2010;|
|Mehta S, Paglia D, Mason K, Graves D, Lin, SS Effect of Diabetes Mellitus upon Fracture Healing Lower Extremity Review Oct 2010|
|Al-Zube L, Breitber EA, O’Connor JP, Parson JR, Bradica G, Hart CE, Lin SS: Recombinant Human Platelet-Derived Growth factor(rhPDGF-BB) and beta-Tricalcium Phosphate/Collagen Matrix Enhance Fracture Healing in a Diabetic Rat Model. J Orthop Research 2009 27(1): 1-12|
|Azad V, Breitbart E, Al-Zube L, Yeh S, O'Conner JP, Lin SS. rhBMP-2 enhances the bone healing response in diabetic rat segmental defect model. J. Orthop. Trauma 2009;23:267-276.|
Areas of Interest
Effect of Bone Marrow upon Orthopedic Biocomposite
Over one million reconstructive surgery, trauma, or abnormal skeletal defect operations are performed in the United States annually. To achieve reconstructive goals, large amounts of autologous or alternative large bulk allograft are needed in the surgical procedure. Allograft bone material and alternatives such as synthetic grafts lack the necessary cellular and other biological components for bony union and healing to occur. A novel approach to overcome these shortcomings would be to apply an artificial periosteum as an adjunct to the allograft treatment that provides osteogenic cells as well as bioactivity to the site to stimulate bone repair. Recently, the natural periosteum has been identified as a critical component for new bone formation in graft incorporation. To our knowledge, no studies have examined the use of an artificial periosteum that incorporates tissue regenerative strategies. Findings to date have shown that the artificial periosteum promotes the osteogenic activity of human bone marrow derived stem cells. The goal of this study is to investigate the use of the composite matrix as an adjunct to allograft treatment in large segmental bone defects.